This author has yet to write their bio.Meanwhile lets just say that we are proud PR Newswire contributed a whooping 998 entries.
Precision Medicine Group acquired Project Farma, a patient-focused bioengineering services firm that supports life science innovators in the manufacturing and scale-up of advanced therapies.
REGENXBIO Inc. provided an update on the RGX-314 programs, including the announcement that the pivotal program for RGX-314 for the treatment of wet age-related macular degeneration (wet AMD) is active.
Apex Innovative Sciences and the company’s affiliates announced their participation in three Covid-19 vaccine studies.
EVERSANA and ArisGlobal announced a strategic partnership to digitally transform end-to-end pharmacovigilance services, leading to safer and more effective healthcare for patients worldwide.
The Janssen Pharmaceutical Companies of Johnson & Johnson submitted a Biologics License Application to the U.S. Food and Drug Administration seeking approval of amivantamab for the treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
Grünenthal agreed to acquire the European rights (excluding Spain and the UK) to AstraZeneca’s Crestor (rosuvastatin) and its associated brands for a total consideration of up to $350 million.
Vitas Healthcare chose Greater Than One (GTO) Group as agency of record to support the hospice company’s transformative focus on brand equity, improved efficiency and enhanced return on investment from its marketing initiatives.
PRECISIONeffect launched a new work-break video series – This Medical Moment – hosted by the healthcare advertising agency’s president, Carolyn Morgan.
Abbott became the first anchor sponsor of the American Diabetes Association’s Health Equity Now platform to address health disparities for people with diabetes.
Heron Therapeutics Inc.’s New Drug Application (NDA) was resubmitted to the U.S. Food and Drug Administration for HTX-011, an investigational agent for the management of postoperative pain.
